Researchers have revealed how a simple blood test could be used to help identify cardiovascular ageing and the risk of heart disease. Also Read - Obesity and Overweight Can Aggravate Alzheimer’s Disease, Even More, Warns Study

The study, published in the Journal of the American College of Cardiology, reported that higher levels of amyloid-beta in the blood may be a key indicator of cardiovascular disease. Also Read - COVID-19: Blood Test to Predict High-Risk COVID Patients, Say Researchers

Amyloid-beta is known to be involved in the development of Alzheimer’s disease, yet researchers have now concluded that it may have a key role to play in vascular stiffening, thickening of the arteries, heart failure and heart disease progression. Also Read - Kangana Ranaut Alleges Ranveer Singh, Ranbir Kapoor, Ayan Mukerji, Vicky Kaushal Are Cocaine Addict, Dare Them to Go Through Blood Test

It is hoped that this research will one day lead to the development of a simple blood test that could be used as a clinical biomarker to identify patients who are most at risk so that preventative measures can be put in place and death rates reduced.

“Our work has created and put all the pieces of the puzzle together. For the first time, we have provided evidence of the involvement of amyloid-beta in early and later stages of cardiovascular disease,” said study researcher Konstantinos Stellos from Newcastle University in the UK.

For the findings, the research team analysed blood samples from more than 6,600 patients from multiple cohort studies in nine countries and found that patients could be divided into high and low-risk categories of heart disease based on their amyloid-beta levels.

“What is really exciting is that we were able to reproduce these unexpected, clinically meaningful findings in patients from around the world. In all cases, we observed that amyloid-beta is a biomarker of cardiovascular ageing and of cardiovascular disease prognosis,” Stellos added.

The study proposed the existence of a common link between both conditions, which has not been acknowledged before and could lead to better patient care.

The findings suggest that the higher the level of amyloid-beta in the blood the higher the risk of developing serious heart complications.

In the future, it is hoped that a simple blood test could be added to the current method of patient screening, known as the GRACE score, which assesses heart attack risk and guides patients’ treatment plans.

Using the GRACE score, eight factors are used to predict the risk of heart attack, including age, blood pressure, kidney function and elevated biomarkers.